- Home
- SCNI vs APVO Comparison
SCNI vs APVO Comparison
Compare SCNI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- APVO
- Stock Information
- Founded
- SCNI 2003
- APVO 2016
- Country
- SCNI Israel
- APVO United States
- Employees
- SCNI N/A
- APVO N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- APVO Health Care
- Exchange
- SCNI Nasdaq
- APVO Nasdaq
- Market Cap
- SCNI 4.6M
- APVO 4.9M
- IPO Year
- SCNI N/A
- APVO N/A
- Fundamental
- Price
- SCNI $1.37
- APVO $1.63
- Analyst Decision
- SCNI
- APVO
- Analyst Count
- SCNI 0
- APVO 0
- Target Price
- SCNI N/A
- APVO N/A
- AVG Volume (30 Days)
- SCNI 95.4K
- APVO 17.1M
- Earning Date
- SCNI 11-21-2025
- APVO 11-06-2025
- Dividend Yield
- SCNI N/A
- APVO N/A
- EPS Growth
- SCNI N/A
- APVO N/A
- EPS
- SCNI 0.26
- APVO N/A
- Revenue
- SCNI $1,147,000.00
- APVO N/A
- Revenue This Year
- SCNI N/A
- APVO N/A
- Revenue Next Year
- SCNI N/A
- APVO N/A
- P/E Ratio
- SCNI $5.20
- APVO N/A
- Revenue Growth
- SCNI 303.87
- APVO N/A
- 52 Week Low
- SCNI $1.20
- APVO $1.32
- 52 Week High
- SCNI $6.18
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- SCNI 45.19
- APVO 47.97
- Support Level
- SCNI $1.32
- APVO $1.62
- Resistance Level
- SCNI $1.63
- APVO $1.84
- Average True Range (ATR)
- SCNI 0.11
- APVO 0.13
- MACD
- SCNI 0.01
- APVO 0.04
- Stochastic Oscillator
- SCNI 38.37
- APVO 41.55
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.